Azilect

Introduction: Parkinson‟s disease (PD) is characterized by a chronic progressive loss of nigrostriatal dopaminergic neurons that… Expand

IMPORTANCE Depression, cognitive impairment, and other nonmotor symptoms (NMSs) are common early in Parkinson disease (PD) and… Expand

Rasagiline (Azilect(®)) is a selective and irreversible monoamine oxidase B inhibitor, which is well tolerated, safe, improves… Expand

This is a case report of a 69-year-old female with Parkinson's disease who developed an asymptomatic eruption on her legs… Expand

KEY POINTS Rasagiline, like selegiline, is an irreversible monoamine oxidase type-B (MAO-B) inhibitor It inhibits the breakdown… Expand

Increasing evidence suggests that oxidative stress (OS)-induced pancreatic β-cell impairments is involved in diabetes and… Expand

Novel therapeutic approaches for the treatment of neurodegenerative disorders comprise drug candidates designed specifically to… Expand

We recently reported that propargylamine derivatives such as rasagiline (Azilect) and its S-isomer TVP1022 are neuroprotective… Expand

The anti-Parkinson monoamine oxidase (MAO)-B inhibitor rasagiline (Azilect) was shown to possess neuroprotective activities… Expand

The therapeutic use of enzyme inhibitors in treatment of neurodegenerative diseases has its origin in the anti Parkinson action… Expand